

Phase I trial: Fortrea Phase I unit Leeds

Submission date 09/01/2025	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 10/01/2025	Overall study status Deferred	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 10/01/2025	Condition category Other	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Contact information

Type(s)

Principal investigator

Contact name

Dr Jim Bush

Contact details

Fortrea Clinical Research Unit Ltd
Drapers Yard
Marshall St
Holbeck
Leeds
United Kingdom
LS11 9EH
+44 (0)1133013590
ukirelandregethics@fortrea.com

Type(s)

Scientific

Contact name

Mr Clinical Scientist

Contact details

Roervangsvej, 30
Holbaek
Denmark

4300
+45 (0)59 48 59 59
info@pharmacosmos.com

Type(s)

Public

Contact name

Mr Head Of Clinical Development

Contact details

Roervangsvej 30
Holbaek
Denmark
4300
+45 (0)59 48 59 59
info@pharmacosmos.com

Additional identifiers

Clinical Trials Information System (CTIS)

2024-000381-25

Integrated Research Application System (IRAS)

1009954

ClinicalTrials.gov (NCT)

Nil known

Protocol serial number

IRAS 1009954 Fortrea Phase I unit Leeds

Study information

Scientific Title

Phase I trial: Fortrea Phase I unit Leeds [The full scientific title will be published within 30 months after the end of the trial]

Study objectives

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Ethics approval required

Ethics approval required

Ethics approval(s)

approved 12/11/2024, North East-York (2 Redman Place, Stratford, London, E20 1JQ, United Kingdom; +44 (0)207 104 8079; york.rec@hra.nhs.uk), ref: 24/NE/0138

Study design

Human AME trial in 6 healthy volunteers and 6 iron-overloaded patients

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Interventions

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Intervention Type

Drug

Phase

Phase I

Drug/device/biological/vaccine name(s)

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Primary outcome(s)

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Key secondary outcome(s)

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Completion date

27/02/2025

Eligibility

Key inclusion criteria

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Participant type(s)

Healthy volunteer, Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Key exclusion criteria

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Date of first enrolment

28/11/2024

Date of final enrolment

12/02/2025

Locations**Countries of recruitment**

United Kingdom

England

Study participating centre**Fortrea Phase I unit**

Drapers Yard

Marshall Street

Leeds

United Kingdom

LS 11 9EH

Sponsor information**Organisation**

Pharmacosmos (Denmark)

ROR

<https://ror.org/04g1gk322>

Funder(s)

Funder type

Industry

Funder Name

Pharmacosmos

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated and/or analysed during the current study are not expected to be made available because of their high commercial sensitivity and the negligible benefit to the public of publication of results of non-therapeutic clinical trials.

IPD sharing plan summary

Not expected to be made available

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes